OPIOID PHE Information Page
OPIOID Public Health Emergency (PHE) Information Page
The mission of Drug Enforcement Administrations (DEA), Diversion Control Division is to prevent, detect, and investigate the diversion of controlled pharmaceuticals and listed chemicals from legitimate sources while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs.
During this National Emergency the Diversion Control Division is working with our Federal partners including ASPR, FEMA, HHS, FDA, ONDCP, SAMSHA, and members of the White House Task Force; DEA registrants; and representatives of the medical and health-care associations to assure that there is an adequate supply of controlled substances in the United States. The DEA will also work to assure that patients will have access to necessary drug products containing controlled substances.
COVID19 Guidance Documents extended to OPIOID Epidemic:
- DEA Guidance (Extended to OPIOID PHE): Q&A Concerning Administering Certain CS in the parking lot of a healthcare provider’s DEA-registered location during the COVID-19 public health emergency (Effective July 28, 2020, DEA-DC-43)
- DEA Policy (Extended via Rulemaking): Exception to Separate Registration Requirements Across State Lines (Effective March 25, 2020, DEA-DC-18)
- DEA Policy (Extended to OPIOID PHE): Use of Unregistered Off-Site Locations in MAT (Effective April 7, 2020, DEA-DC-25)
- DEA Policy (Extended to OPIOID PHE): Use of Unregistered Off-Site Locations in MAT (Buprenorphine) (Effective April 28, 2020, DEA-DC-30)
- DEA Policy (Extended via Rulemaking): Use of Telephone Evaluations to Initiate Buprenorphine Prescribing (Effective March 31, 2020, DEA-DC-22)
- DEA Guidance (Extended to OPIOID PHE): Exemption Allowing Alternate Delivery Methods for OTPs (Effective March 16, 2020, DEA-DC-15)
- DEA Policy (Extended to OPIOID PHE): Exception to Regulations to Email or Fax DEA Form 222s (Effective March 26, 2020, DEA-DC-019)